滚动资讯
Endpoints NewsRezdiffra is exceeding Wall Street's expectations as the MASH market takes shapeBioPharma DiveGSK cuts deal with Sino to broaden reach of hepatitis B drugEndpoints NewsDaiichi eyes almost $15B in oncology sales by 2030 in ADC franchise pushEndpoints NewsNew home for Novo's Parkinson's cell therapy; GSK turns to China for hep B drugClinical OMICsBrain-Controlled Hearing Aid Singles Out Voices in a CrowdBioWorldFirst cruise ship hantavirus genome points to zoonotic spilloverBioWorldBiggest gainers and losers for May 4-8, 2026Endpoints NewsInhibrx says combo therapy shrank more tumors than Merck's Keytruda aloneFierceBiotechAmid M&A buzz, Inhibrx's OX40-Keytruda combo shows promise in early look at midphase dataFierceBiotechDaiichi Sankyo targets global top 5 oncology rank by 2035, $1.3B efficiency drive in new 5-year planPLoS BiologyThe problem with one-size-fits-all medicine: Biological sex and the aging immune systemPLoS BiologyUSP39 promotes antiviral defense through post-transcriptional control of RIG-I and stabilization of STING

资讯库

最新 最旧
总数 10738
页码 211 / 597
搜索 --